Anlotinib plus the new Immune Checkpoint Inhibitors. Clinical Trials

1 actively recruiting trial

Also known as: Pembrolizumab, Sintilimab etc. have not been used in the previous treatment.

Filter by location:

Other1 trial

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.